| Oct 17 |
Prediction: These 2 Stocks Could Soar in 2025
|
| Oct 15 |
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know
|
| Oct 15 |
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
|
| Oct 15 |
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
|
| Oct 10 |
Recursion, Exscientia seek support for merger ahead of special meeting
|
| Oct 9 |
Why Recursion is getting love as an AI and drug discovery top pick
|
| Oct 8 |
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|
| Oct 7 |
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
|
| Oct 2 |
Recursion gains FDA nod to study cancer drug
|
| Oct 2 |
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
|
